Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of VLPCOV-01 SARS-CoV-2 vaccine
jRCT2071210067Phase 1Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised trial in coronavirus disease 2019 (COVID-19) comparing VLPCOV-01 with Matching placebo (2 arms). Primary endpoints: Solicited local and systemic reactogenicity adverse events and Unsolicited adverse events. Started Sep 2021; status: completed.
02
Drugs
VLPCOV-04
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071210067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210067.